Overdiagnosis in lung cancer screening

Affiliations

¹ Department of Respiratory Medicine, Leeds Teaching Hospitals, St James's University Hospital, Leeds LS9 7TF, UK. Electronic address: matthew.callister@nhs.net.
² School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
³ International Agency for Research on Cancer, Lyon, France.

Matthew E J Callister et al. Lancet Respir Med. 2021 Jan.

. 2021 Jan;9(1):7-9.

doi: 10.1016/S2213-2600(20)30553-1.

¹ Department of Respiratory Medicine, Leeds Teaching Hospitals, St James's University Hospital, Leeds LS9 7TF, UK. Electronic address: matthew.callister@nhs.net.
² School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
³ International Agency for Research on Cancer, Lyon, France.

No abstract available

Conflict of interest statement

Conflicts of Interest

None

1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011. Aug 4;365(5):395–409. - PMC - PubMed
1. Patz EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014. Mar 1;174(2):269–74. - PMC - PubMed
1. Black WC, Chiles C, Church TR, Gareen IF, Gierada DS, Mahon I, et al. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019. Jul 3; - PMC - PubMed
1. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020. Jan 29;10.1056/NEJMoa1911793. - DOI - PubMed
1. Blom EF, Ten Haaf K, de Koning HJ. Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates. Lung Cancer. 2020. Jan;139:200–6. - PubMed